• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fink Densford

pSividia eyes knee market, releases earnings

September 10, 2015 By Fink Densford

pSivida (NSDQ:PSDV) released its fiscal year earnings for 2015 yesterday and said it’s eyeing an entrance into the orthopedic knee market with a new drug-device implant. The company said it is slated to submit an investigational new drug application with the FDA and begin a study of a new implant using its Durasert technology to […]

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: pSivida Corp.

QT Vascular wins CE Mark for drug-coated balloon

September 9, 2015 By Fink Densford

QT Vascular said Monday it won CE Mark approval in the European Union for its Chocolate Touch drug-coated balloon for treating vascular disease. The device is a paclitaxel coated balloon meant to treat occluded arteries and mechanically dilate them with a balloon catheter, the company said. Singapore-based medical company said it expects a commercial launch of […]

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: QT Vascular

Intersect ENT's Propel study meets endpoint

August 17, 2015 By Fink Densford

Intersect ENT (NSDQ:XENT) said a new study of its Propel mini steroid-releasing sinus implant used after frontal sinus surgery met the primary endpoint in a clinical trial. The Propel device is already approved for use in the ethmoid sinuses, behind the bridge of the nose, in conjunction with sinus surgery to treat symptoms of chronic sinusitis, […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Intersect ENT Inc.

SteadyMed still steady on Q2

August 14, 2015 By Fink Densford

SteadyMed Therapeutics (NASDAQ:STDY) yesterday released quarterly earnings that missed expectations and reported growing losses, but shares stayed steady. SteadyMed is a developer of hypertension and pain treatments given with a discrete, patented drug-delivery device called the PatchPump. The company is focusing on development and approval of Treyvant, a drug to treat pulmonary arterial hypertension. SteadyMed reported losses of […]

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: SteadyMed Therapeutics

Bard, Medtronic win Medicare reimbursement add-on for DCBs

August 3, 2015 By Fink Densford

Medtronic (NYSE:MDT) and C.R. Bard (NYSE:BCR) said today that angioplasty treatments with  drug-coated balloons will now be eligible for new technology add-on payments through the Centers for Medicare and Medicaid Services under Medicare’s hospital impatient prospective payment systems. The add-on payment, with a maximum of $1,036, will help cover additional costs for treating patients for peripheral artery disease with […]

Filed Under: Drug-Device Combinations Tagged With: C.R. Bard, Centers for Medicare and Medicaid Services (CMS)

Intersect Ent launches Nova sinus implant trial

July 9, 2015 By Fink Densford

Intersect ENT (NSDQ:XENT) said yesterday it enrolled the 1st patient in a trial of its Nova bioabsorbable steroid releasing sinus implant. The implant is designed to prop open the sinuses and deliver anti-inflammatory medication after surgical interventions, the Menlo Park, Calif.-based company said. “Clinical evidence to date has shown that Propel and Propel mini meaningfully […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Intersect ENT Inc.

Delcath to settle shareholder suits for $8.5m

July 8, 2015 By Fink Densford

Delcath (NSDQ:DCTH) said yesterday that it agreed to pay $8.5 million to settle a clutch of lawsuits filed by shareholders over losses related to its development of the drug-device combination Melblez kit. The lawsuits, filed by shareholders in 2013, sought compensation for losses between April 21, 2010, and May 2, 2013, stemming from 3 separate incidents the plaintiffs claim caused […]

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Delcath Systems Inc.

Diabetes: Medtronic furthers the quest for an artificial pancreas

June 15, 2015 By Fink Densford

Medtronic (NYSE:MDT) and Intarcia Therapeutics were in the spotlight at the American Diabetes Assn.’s annual scientific sessions conference in Boston last week, revealing new medical device developments in the fight against diabetes. Medtronic took center stage, announcing new developments for its artificial pancreas program, touting positive data from a user study of its MiniMed 640g and revealing plans to collaborate […]

Filed Under: Clinical Trials, Drug-Device Combinations, Research & Development Tagged With: Becton Dickinson, GI Dynamics, Glytec, Intarcia Therapeutics, Medtronic, Valeritas Inc.

Intersect ENT PO goes over-allotment, closes at $103m

June 11, 2015 By Fink Densford

Intersect ENT (NSDQ:XENT) said Tuesday it closed its public offering of 4.1 million shares of common stock at $25 per share. J.P. Morgan and BofA Merrill Lynch were book-runners for the offering, with Leerink Partners, Canaccord Genuity and William Blair as co-managers, the company said.. The deal included 537,300 shares sold through an underwriters option to purchase […]

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Intersect ENT Inc.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 20
  • Page 21
  • Page 22

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS